

Agenda

Lung Research Day

S Y M P O S I U M

April 12, 2011

1 p.m. – The tour of the California National Primate Resource Center

5-8 p.m. – Reception, Poster Exhibit and Panel Discussion

Walter H. Buehler Alumni and Visitor's Center

Alumni Lane, UC Davis, Davis, CA

(Spaces are limited. Registration is required)

April 13, 2011

9 a.m.-5 p.m. – Speaker Presentations

Genome and Biomedical Sciences Facility, Auditorium

451 Health Sciences Dr., Davis, CA

(Registration is required)

To Register:

www.ucdmc.ucdavis.edu/ctsc/areas/partnering/index.html

UCDAVIS
HEALTH SYSTEM

**Clinical and Translational
Science Center**

in collaboration with:

Tuesday, April 12, 2011

Agenda

1 p.m. **A tram tour of the California National Primate Resource Center and the Inhalation Exposure facilities**

The largest academic primate facility with respiratory research as the primary focus. The tour is led by Dr. Dallas Hyde, Director of the Center. Please contact kate.marusina@ucdmc.ucdavis.edu to schedule. **Space is limited to 12 participants.** Proof of negative TB/measles is **not** required for the basic tram tour. Those wishing to visit the animal rooms in addition to the tour need to provide the documentation of negative TB/measles.

5–8 p.m. **Reception, Poster Exhibit and the Panel**

Walter H. Buehler Alumni and Visitor's Center

(link to map: www.alumni.ucdavis.edu/s/787/NoRtCol.aspx?sid=787&gid=1&pgid=372)

5 p.m. **Networking Reception and Poster Exhibit**

Evening Networking Reception with clinical and basic sciences faculty, postdoctoral and graduate students, and industry partners and Poster Exhibit. Up to 28 posters will be selected for the Exhibit. The poster authors will be available for questions.

6 p.m. **Panel Discussion – Controversies in inhaled drug delivery: small molecules or biologics?**

Introductory Remarks: Mark Avdalovic, M.D., Assistant Clinical Professor, Division of Pulmonary and Critical Care, UC Davis Medical Center

Panel:

- **Robert B. Fick, Jr, M.D.**, Senior Director, Merck Research Labs, Head, Biologics Strategy, Resp & Immunology
- **Igor Gonda, Ph.D.**, President & Chief Executive Officer, Aradigm
- **Professor Clive Page, Ph.D.**, Chairman of the Board, Verona Pharmaceuticals, Director, Sackler Institute of Pulmonary Pharmacology, King's College London
- **David Lechuga, Ph.D.**, Principal Scientist, Particle Sciences and Technology, Pearl Therapeutics
- **Brian Morrissey, M.D.**, Associate Professor, Division of Pulmonary and Critical Care, UC Davis Medical Center

Brief Bios of the Panel Participants

Dr. Robert Fick, M.D.

Senior Director, Merck Research Labs

Robert B. Fick, Jr., M.D. is Senior Director, Merck Research Labs, Head, Respiratory & Immunology Strategy for the New MRL Biologics organization. The Palo Alto labs identify novel targets in key inflammatory pathways, extend the evidence of pathogenic involvement in human disease, and early development plans for novel biologic drugs. He is Adjunct Clinical Professor of Medicine, Stanford University School of Medicine, Division of Pulmonary and Critical Care Medicine.

Dr. Fick has contributed over 200 published papers of original science, textbooks, review articles and chapters.

He has been elected Fellow in the American College of Physicians and Fellow of the American College of Chest Physicians. As a member of the American Thoracic Society he served as President of the National Council, member of the Board of Directors and Research Coordinating Committee of this international organization.

Dr. Fick received his Doctor of Medicine degree from Northwestern University School of Medicine, Chicago, IL and continued with Postdoctoral training in Internal Medicine and in Pulmonary & Critical Care Medicine at Yale University School of Medicine, New Haven, CT. He served as a tenured Professor of Medicine, Division of Pulmonary & Critical Care Medicine, University of Iowa, before relocating to California.

Brief Bios of the Panel Participants *(continued)*

David Lechuga, Ph.D.

Principal Scientist, Pearl Therapeutics

Principal Scientist, Particle Sciences and Technology
Dr. Lechuga-Ballesteros has over sixteen years of industrial experience, most of them devoted to the development of inhalation products. Prior to Pearl, David worked at Aridis Pharmaceuticals developing inhaled human monoclonal antibodies and antibiotic formulations for the treatment of cystic fibrosis; and at Nektar Therapeutics where he established and directed the pharmaceutical materials sciences function which enabled the design of dispersible and stable spray dried powders for inhalation, such as Exubera®, inhaled insulin. He contributed to the development of Norvir®, a protease inhibitor for the treatment of AIDS at Abbott Laboratories. David is a leading applied scientist in the field of physical pharmacy, with co-authorship of more than 80 publications (peer reviewed papers, book chapters, invited reviews and abstracts), and inventorship on more than a dozen patents. David is an Adjunct Associate Professor at the University of Connecticut, and a member of the Editorial Advisory Board of the Journal of Pharmaceutical Sciences, Pharmaceutical Research, and Molecular Pharmaceuticals. He is also a Steering Committee member of the AAPS Nanotechnology Focus Group.

David earned his B.S. from the Universidad Nacional Autónoma de México in 1984, and Ph.D. in Pharmaceutics from the University of Michigan, Ann Arbor in 1993.

Professor Clive Page, Ph.D.

Chairman of the Board, Verona Pharmaceuticals

Professor Page, chairman of Verona Pharma since September 2006, is a Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology in the Division of Pharmaceutical Sciences, King's College, University of London. He is a recognized authority in the area of lung diseases and inflammation, as well as being internationally recognized for his work in connection with heparin and related molecules as anti-inflammatory drugs. He is highly regarded internationally as a consultant to both the pharmaceutical and biotech industries and he is currently a consultant to Johnson & Johnson and Z-cube, the venture capital arm of Zambon Group S.p.A. His academic research has resulted in more than 200 scientific publications and he

has edited a number of leading books in pharmacology of lung diseases. Professor Page is one of the inventors of the NAIPS technology being developed by Verona Pharma.

Igor Gonda, Ph.D.

President & Chief Executive Officer, Aradigm

Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of AcruX Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

Brian Morrissey, M.D.

Associate Professor, Division of Pulmonary and Critical Care, UC Davis Medical Center

Dr. Morrissey has extensive experience managing patients with cystic fibrosis and bronchiectasis. He is skilled at performing a wide range of technically difficult procedures, including double-lumen intubation, whole-lung lavage and brachyradiation catheter placement. Dr. Morrissey's research focuses on airway disease and cystic fibrosis. He is studying the influence of oxidation on the pulmonary pathology of patients with cystic fibrosis.

Registration is required. Dinner buffet is catered by the Sodexo Catering. Cash bar.

Wednesday, April 13, 2011 • 9 a.m. – 5 p.m.

Speaker Presentations

Genome and Biomedical Sciences Facility, Auditorium

451 Health Sciences Dr., Davis, California

(Registration is required)

- 9 a.m. **Keynote Presentation**
Mark Avdalovic, M.D., M.A.S, FCCP
 Assistant Clinical Professor, Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis Medical Center. Highlights of UC Davis resources and intra-campus collaborations in the respiratory space. The introduction covers the airway biology program, the environment/biology center, the California National Primate Center, tissue bank, EMR and clinical data bases.
- 9:15 **Host Immune Reactions in the Lung**
Grace Li-Ying Hung
 Laboratory of Reen Wu, Ph.D., Professor, Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine and Center for Comparative Respiratory Biology and Medicine (CCRBM). Interleukin-17A and Interleukin-19 in Regulating Airway Epithelial Immunity.
- 9:40 **Stan Tam, Ph.D.**
 Laboratory of Dallas Hyde, Ph.D., Professor & Director, California National Primate Research Center Characterization of gamma delta T-lymphocytes in pulmonary Nocardiosis.
- 10:05 **Pam Lein, Ph.D.**
 Associate Professor, Department of Molecular Biosciences Atopic status determines inflammatory cell mediators in organophosphorus pesticide-induced airway hyperreactivity.
- 10:30 **Coffee Break**
- 10:50 **Lung and the Environment – Session I**
Brian Moore, Ph.D.
 Laboratory of Edward Schelegle, Ph.D., Associate Professor, School of Veterinary Medicine The role of serotonin in airway smooth muscle contraction in a model of childhood asthma.
- 11:15 **Fern Tablin VMD, Ph.D.**
 Professor of Anatomy, Physiology and Cell Biology Exposure to ambient particulate matter results in platelet activation and systemic cytokine up-regulation: precursors to cardiovascular disease.
- 11:40 **Tzipora Goldkorn, Ph.D.**
 Professor, Division of Pulmonary, Critical Care and Sleep Medicine COPD and sphingomyelin.
- 12 – 1:30 p.m. **Lunch/MBF Biosciences Presentation**
Julie Simpson, Ph.D.
 Staff Scientist, Research Liaison, MBF Bioscience Applying the Principles of Design-Based Stereology to Pulmonary Studies.
- 1:30 **Lung and the Environment – Session II**
Dallas Hyde, Ph.D.
 Professor & Director, California National Primate Research Center Effect of ozone on late alveolarization.
- 1:55 **Dennis W. Wilson, Ph.D.**
 Professor and Chair, Department of Pathology Microbiology and Immunology, School of Veterinary Medicine Heart Failure and the Lung: A roundabout trip from the lung to the failing heart and back.
- 2:20 **Coffee Break**
- 2:50 **Translational Studies**
Richard Harper, M.D.
 Associate Professor, Division of Pulmonary, Critical Care and Sleep Medicine Use of UC Davis tissue repository to study airway diseases.
- 3:15 **Amir A. Zeki, M.D.**
 Assistant Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine Statins and Airway Disease.
- 3:40 **Mark Avdalovic M.D., M.A.S, FCCP**
 Assistant Clinical Professor, Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis Medical Center; Medical Director, UC Davis Medical Group Outpatient PFT Lab COPD: the heart of the matter.
- 4 p.m. **Closing Remarks**